Sorry, you need to enable JavaScript to visit this website.
Skip to main content

This site is intended for US healthcare professionals only.

This site is intended for US healthcare professionals only.

Don’t just inhibit yeast growth

Kill it with BREXAFEMME1

Don’t just inhibit yeast growth

Kill it with BREXAFEMME1

A broad-spectrum* triterpenoid antifungal with fungicidal activity1

  • bullet-point-iconBREXAFEMME is not an azole. It belongs to a novel class known as triterpenoid antifungals1
  • bullet-point-iconIt works by blocking glucan synthase, an enzyme present in fungal cells but not human cells1
  • bullet-point-iconThis disrupts the fungal cell wall integrity, leading to cell death. This fungicidal activity kills Candida1*

See the fungicidal activity of BREXAFEMME in action1

BREXAFEMME has broad-spectrum activity1*

Clinical efficacy shown vs Candida albicans tick mark
In vitro activity vs non-albicans Candida tick mark
In vitro activity vs azole-resistant strains tick mark
Exceptional vaginal tissue penetration tick mark
Retains activity in low pH tick mark

*Based on in vitro studies. Clinical significance is unknown.1

In animal studies, BREXAFEMME exhibited exceptional vaginal tissue penetration after oral administration—reaching up to 9 times the plasma concentration.1

BREXAFEMME retained antifungal activity based on minimal inhibitory concentration values when tested at pH 4.5 (the normal vaginal pH).1

SAY NO MORE to vaginal yeast infections.
Prescribe BREXAFEMME today.

SAY NO MORE to vaginal yeast infections. Prescribe BREXAFEMME today.

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

References

1. BREXAFEMME. Prescribing Information. SCYNEXIS, Inc.; 2021. 2. Data on file. SCYNEXIS, Inc., Jersey City. NJ.

Important Safety Information

Indication

/ / / /
  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

Read full Important Safety Information